O

Oregon Dermatology & Research Center | Portland, OR

Research site

(Unclaimed)

Location

2565 NW Lovejoy, Suite #200, Portland, Oregon, United States of America

Site insights

Top conditions

Top treatments

VT-1161

NAFT-600

JNJ-77242113

Doxycycline

Tavaborole

Risankizumab

Terbinafine

Sofpironium Bromide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 12 total trials

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting

Plaque Psoriasis

Drug: Deucravacitinib Matching Placebo

Drug: JNJ-77242113 Matching Placebo

Locations recently updated

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Enrolling

Moderate Plaque Psoriasis

Drug: Risankizumab

Drug: Deucravacitinib

To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

The key objective is to establish the efficacy, safety, tolerability, and pharmacokinetics of investigational drug Hallux Terbinafine Subungual Gel (...

Active, not recruiting

Onychomycosis of Toenail

Drug: Hallux Terbinafine Subungual Gel